[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Azitra Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100579943","phase-1-a-study-to-evaluate-topical-atr04-484-for-egfri-associated-dermal-toxicity-100579943",false,"NCT06830863","A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity","A Phase 1\u002F2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety, Bioavailability, and Effect of Topically Administered ATR04-484 for Moderate to Severe EGFRi-Associated Dermal Toxicity","Inclusion Criteria:\n\n* Adults ≥18 years of age\n* Has Grade 2 or 3 non-infected moderate to severe EGFRi-related dermal toxicity affecting the face (the neck, chest, back and other areas may also be affected)\n\nExclusion Criteria:\n\n* Significant skin disease other than EGFRi-related dermal toxicity\n* Treatment with topical mid- to high-potency topical corticosteroids, or topical antibiotics or antibacterial washes on the face, neck, chest, or back within 14 days prior to baseline; treatment with systemic antibiotics or systemic corticosteroids within 14 days prior to baseline\n* Residing with an immunocompromised person residing with them in the same dwelling from the baseline visit through 2 weeks after the treatment period","ALL","18 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The goal of this randomized clinical trial is to learn if topical treatment with ATR04-484 can treat skin rash in patients undergoing EGFR inhibitor (EGFRi) therapy. The primary goal of the study is to determine safety and tolerability of ATR04-484, and the secondary goal of the study is to assess efficacy signals of ATR04-484. Researchers will compare treatment of ATR04-484 to its vehicle. Participants will:\n\n* Apply ATR04-484 or vehicle daily for 28 days\n* Visit the clinic periodically for evaluation and sample collection",[27],"EGFR Inhibitor-associated Rash",[29,30,31,32],"EGFR","acneiform","EGFR inhibitor-associated rash","EGFRi","RECRUITING","2026-02-09",{"date":36,"type":37},"2026-02-11","ACTUAL",{"date":39,"type":37},"2025-08-25",{"date":41,"type":20},"2027-02-15",{"name":43,"class":44},"Azitra Inc.","INDUSTRY",6,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":5},"100526623","phase-1-evaluation-of-topical-atr12-351-in-adults-with-netherton-syndrome-100526623","NCT06137157","Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome","A Randomized, Double-Blind, Vehicle-Controlled, First-in-Human Safety, Tolerability and Proof-of-Concept Study of Topical ATR12-351 in Adults With Netherton Syndrome","Inclusion Criteria:\n\n* Adults ≥18 years of age\n* Confirmed mutation of the serine protease inhibitor of Kazal type 5 (SPINK5) gene\n* Involvement of ≥20% of body surface area with skin changes consistent with Netherton syndrome\n\nExclusion Criteria:\n\n* Use of biologic therapies, antibiotics, antihistamines, corticosteroids, retinoids, disease-modifying antirheumatic drugs (DMARDs), immunosuppressive agents, phosphodiesterase-4 (PDE4) inhibitors, topical calcineurin inhibitors, or topical Janus kinase (JAK) inhibitors\n* Open wounds or extensive areas of excoriation precluding identification of appropriate application sites in the Investigator's judgment\n* Concurrent involvement in any other clinical study\u002Fexpanded access program with an investigational drug or device or has participated in a clinical study within 30 days prior to the screening visit\n* Residing with an immunocompromised person in the same dwelling from the baseline visit through 2 weeks after the treatment period\n* History of ultraviolet phototherapy within the planned treatment area 4 weeks prior to baseline",{"count":54,"type":20},12,[23],"The objectives of this clinical trial are to evaluate the safety and tolerability of topically applied ATR12-351, to understand what the body does to ATR12-351, and to observe treatment benefits of the drug in approximately 12 adult patients with Netherton Syndrome (NS). ATR12-351 will be applied to skin lesions on one side of the body, while the vehicle control will be applied to similar lesion on the other side of the body twice daily for 2 weeks.",[58],"Netherton Syndrome",[60,61,62,63],"Ichthyosis","Netherton syndrome","Skin disease","ichthyosis linearis circumflexa","2026-02-04",{"date":66,"type":37},"2026-02-05",{"date":68,"type":37},"2024-06-19",{"date":70,"type":20},"2026-08-01",{"name":43,"class":44},""]